Drug Development · global
Making Sunlight Less Painful: Bitopertin Meets Phase 3 Trial Endpoints, Resubmission Planned by Year-End
A trial involving 183 participants showed that oral bitopertin can reduce protoporphyrin accumulation and increase patients’ time in sunlight without pain. The efficacy signals extend beyond blood tests into daily life, but further evidence on long-term benefits and safety is still needed.
For patients with erythropoietic protoporphyria (EPP), stepping into sunlight can bring severe pain, requiring careful planning even for everyday outings. Disc Medicine announced on October 19 that its oral drug candidate bitopertin met all primary and secondary efficacy endpoints in the Phase 3 APOLLO trial. At month six, patients had 12.2 more hours of pain-free sunlight exposure per month than those receiving placebo, providing new treatment evidence for this rare disease.
EPP stems from abnormal heme synthesis, which leads to the accumulation of photoactive protoporphyrin IX (PPIX). Exposure to light triggers reactions such as pain and burning and may also damage the hepatobiliary system. Bitopertin inhibits glycine transporter 1 (GlyT1), reducing PPIX production by modulating heme synthesis. Dermatology Times cited an analysis by Yale dermatologist Christopher Bunick explaining that this strategy directly targets the biochemical problem responsible for phototoxicity. However, whether lowering PPIX can prevent long-term liver complications is not a question these results can yet answer.
APOLLO is a randomized, double-blind, placebo-controlled trial involving 183 patients aged 12 and older with EPP or X-linked protoporphyria (XLP) across North America, Europe, and Australia. Participants received 60 milligrams of bitopertin or placebo daily for six months. The two co-primary endpoints assessed PPIX in the blood and how much pain-free time patients could actually spend in sunlight, allowing biochemical changes to be compared with improvements in daily life.
According to the company’s announcement, the change from baseline in whole-blood metal-free PPIX showed a 41.4% reduction compared with placebo (p<0.0001), while monthly pain-free sunlight exposure at month six increased by 12.2 hours (p=0.0010). The presentation explained that the latter measure counted sunlight exposure between 10 a.m. and 6 p.m. on days without pain from phototoxic reactions, using 28-day intervals. This is an average difference between the two groups and should not be interpreted as every patient consistently gaining the same amount of time.
Other results also pointed to better light tolerance. The company’s presentation showed that the incidence of phototoxic reactions over six months was 71% lower than with placebo. An analysis limited to adults found that the improvement from baseline in mean daily exposure time from the start of sunlight exposure to the onset of prodromal symptoms was 56 minutes greater than with placebo. These measures reflect the frequency of painful episodes and the time patients could tolerate sunlight before symptoms appeared, respectively, adding insights into daily life that a single blood measurement cannot capture.
Regarding safety, dizziness was the most common adverse event, occurring in 50% of the bitopertin group and 11% of the placebo group. The company said all dizziness was mild or moderate, generally transient, and occurred early in treatment. Neither group had any withdrawals from the trial due to adverse events. These remain six-month controlled data; for patients who may need long-term medication, extended follow-up will help clarify the benefits and burdens of continued treatment.
The results released so far are still preliminary aggregate findings, with full data expected to be presented at a subsequent medical conference. Dermatology Times noted that the news release did not report how many patients reached specific improvement thresholds. Although the company’s presentation added baseline data, these remain insufficient to fully assess benefits for individual patients and different subgroups. Disc plans to resubmit its New Drug Application to the U.S. Food and Drug Administration by the end of 2026 and expects a decision in mid-2027. This is the company’s estimated timeline; bitopertin is not currently approved for use as a treatment.